Kodiak Sciences (KOD) Stock Forecast & Price Target

Compare

437 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KOD Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Kodiak

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KOD Stock 12 Month Forecast

Average Price Target

$41.75

▲(65.15% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is $41.75 with a high forecast of $50.00 and a low forecast of $38.00. The average price target represents a 65.15% change from the last price of $25.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","51":"$51","13.5":"$13.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13.5,26,38.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,26.10153846153846,28.09307692307692,30.084615384615383,32.076153846153844,34.067692307692305,36.059230769230766,38.050769230769234,40.04230769230769,42.033846153846156,44.02538461538461,46.01692307692308,48.00846153846154,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,25.466923076923077,26.823846153846155,28.18076923076923,29.537692307692307,30.894615384615385,32.25153846153846,33.60846153846154,34.965384615384615,36.32230769230769,37.67923076923077,39.036153846153844,40.39307692307692,{"y":41.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,25.178461538461537,26.246923076923075,27.315384615384616,28.383846153846154,29.45230769230769,30.520769230769233,31.58923076923077,32.65769230769231,33.72615384615385,34.79461538461538,35.863076923076925,36.931538461538466,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.43,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.76,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$41.75

Lowest Price Target$38.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Maury Raycroft

Jefferies

$39

Buy

54.27%

Upside

Reiterated

02/20/26

Analysts Are Bullish on Top Healthcare Stocks: CervoMed (CRVO), Kodiak Sciences (KOD)

Matthew Caufield

H.C. Wainwright

$38

Buy

50.32%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Protara Therapeutics (NASDAQ: TARA) and Kodiak Sciences (NASDAQ: KOD)

Patrick Dolezal

LifeSci Capital

$40

Buy

58.23%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD) and Entera Bio (NASDAQ: ENTX)

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

02/02/26

Kodiak Sciences: GLOW2 Readout as Key Catalyst for Tarcocimab Upside and Broader Pipeline Optionality

Michael Yee

UBS

$50

Buy

97.78%

Upside

Initiated

01/06/26

Kodiak Sciences assumed with a Buy at UBSKodiak Sciences assumed with a Buy at UBS

Gena Wang

Barclays

$17

Hold

-32.75%

Downside

Reiterated

11/17/25

Barclays Sticks to Its Hold Rating for Kodiak Sciences (KOD)

Daniil Gataulin

Chardan Capital

$14

Hold

-44.62%

Downside

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Spero Therapeutics (NASDAQ: SPRO), Kodiak Sciences (NASDAQ: KOD) and VolitionRX (NYSE MKT: VNRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Maury Raycroft

Jefferies

$39

Buy

54.27%

Upside

Reiterated

02/20/26

Analysts Are Bullish on Top Healthcare Stocks: CervoMed (CRVO), Kodiak Sciences (KOD)

Matthew Caufield

H.C. Wainwright

$38

Buy

50.32%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Protara Therapeutics (NASDAQ: TARA) and Kodiak Sciences (NASDAQ: KOD)

Patrick Dolezal

LifeSci Capital

$40

Buy

58.23%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD) and Entera Bio (NASDAQ: ENTX)

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

02/02/26

Kodiak Sciences: GLOW2 Readout as Key Catalyst for Tarcocimab Upside and Broader Pipeline Optionality

Michael Yee

UBS

$50

Buy

97.78%

Upside

Initiated

01/06/26

Kodiak Sciences assumed with a Buy at UBSKodiak Sciences assumed with a Buy at UBS

Gena Wang

Barclays

$17

Hold

-32.75%

Downside

Reiterated

11/17/25

Barclays Sticks to Its Hold Rating for Kodiak Sciences (KOD)

Daniil Gataulin

Chardan Capital

$14

Hold

-44.62%

Downside

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Spero Therapeutics (NASDAQ: SPRO), Kodiak Sciences (NASDAQ: KOD) and VolitionRX (NYSE MKT: VNRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kodiak Sciences

3 Months

xxx

Success Rate

4/5 ratings generated profit

Average Return

+8.40%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +8.40% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

4/5 ratings generated profit

Average Return

-1.22%

reiterated a buy rating 22 days ago

Copying Anupam Rama's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of -1.22% per trade.

2 Years

xxx

Success Rate

3/5 ratings generated profit

Average Return

-27.72%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of -27.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KOD Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KOD has received 6 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. KOD average Analyst price target in the past 3 months is 41.75.

Each month's total comprises the sum of three months' worth of ratings.

KOD Financial Forecast

KOD Earnings Forecast

Next quarter’s earnings estimate for KOD is -$1.03 with a range of -$1.21 to -$0.86. The previous quarter’s EPS was -$1.16. KOD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year KOD has Performed in-line its overall industry.

No data currently available

KOD Sales Forecast

Next quarter’s sales forecast for KOD is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KOD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year KOD has Performed in-line its overall industry.

KOD Stock Forecast FAQ

What is KOD’s average 12-month price target, according to analysts?

Based on analyst ratings, Kodiak Sciences Inc’s 12-month average price target is 41.75.

What is KOD’s upside potential, based on the analysts’ average price target?

Kodiak Sciences Inc has 65.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KOD a Buy, Sell or Hold?

Kodiak Sciences Inc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kodiak Sciences Inc’s price target?

The average price target for Kodiak Sciences Inc is 41.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $38.00. The average price target represents 65.15% Increase from the current price of $25.28.

What do analysts say about Kodiak Sciences Inc?

Kodiak Sciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of KOD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Kodiak Sciences (KOD) Stock Forecast & Price Target

KOD Analyst Ratings

KOD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kodiak Sciences

KOD Analyst Recommendation Trends

KOD Financial Forecast

KOD Earnings Forecast

KOD Sales Forecast

KOD Stock Forecast FAQ

Detailed List of Analyst Forecasts